Roche Holding AG (SWX:RO)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 207.20B |
| Revenue (ttm) | 62.40B |
| Net Income (ttm) | 8.28B |
| Shares Out | n/a |
| EPS (ttm) | 10.31 |
| PE Ratio | 25.03 |
| Forward PE | n/a |
| Dividend | 9.70 (3.60%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 34,871 |
| Average Volume | 37,316 |
| Open | 275.20 |
| Previous Close | 271.40 |
| Day's Range | 272.40 - 276.20 |
| 52-Week Range | 232.40 - 333.60 |
| Beta | 0.22 |
| RSI | 42.37 |
| Earnings Date | Apr 25, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking alg...
Roche’s $50bn US move fuels MEP doubts over EU’s grip on pharma
Amid fears of a pharmaceutical exodus, some MEPs are positioning the EU’s pharmaceutical package as the remedy.
Swiss pharma giant Roche pledges to invest €47 billion in the US
The investment plans include new R&D sites in four US states and creating more than 12,000 jobs, according to the Swiss pharmaceutical company.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2201330218-e972db4cd2d14caf814dfb482e2f39d4.jpg)
Swiss Pharma Giant Roche To Invest $50B in US Amid Tariff Threat
Swiss drugmaker Roche said it plans to invest $50 billion in the U.S., the latest in a string of large companies boosting their presence in the country since President Donald Trump came into office.
Swiss drugmaker Roche leans into Trump tariff formula with $50 billion promise to invest in U.S.
Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.
Swiss drugmaker Roche to invest $50bn in US manufacturing amid tariff fears
Company says it will create more than 12,000 new jobs as pharmaceutical industry braces for Trump levies The Swiss drugmaker Roche has announced it will put $50bn (£37bn) into manufacturing in the US ...
Swiss pharma giant Roche to invest $50 billion in US amid growing tariff uncertainty
Roche, a Swiss pharmaceutical giant, will invest $50 billion in the United States over the next five years, creating 12,000 jobs and expanding manufacturing, distribution, and research. This decision,...
European markets mixed as investors returned from Easter break, NVO and Roche in focus
Roche invests $50 billion in US in hopes of dodging Trump tariffs
Trump's looming tariff threats have prompted several announcements, even as the EU is pleads for more investment in Europe.
Roche to park $50B in U.S. over five years, create 12,000 jobs
Roche to invest $50 billion in the U.S. as tariff threat lingers
Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the United States.
Roche to spend $50bn on US manufacturing and R&D
Swiss group becomes latest pharmaceutical company to promise investment in the face of potential tariffs
Pharma giant Roche pledges $50 billion US investment in R&D, manufacturing
Swiss pharmaceutical giant Roche unveiled ambitious plans on Tuesday for a substantial $50 billion investment in the United States over the coming five years. This significant commitment represents on...
Roche to Invest $50 Billion in U.S. Manufacturing, R&D Amid Tariff Threats
The pharma giant said the investment would create more than 12,000 new jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump's tariff threats.
Roche to invest $50 billion in United States over next five years
Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of the biggest inward investment moves by companies dealing with President Donald Trump's tariffs...
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
Basel, 22 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengt...
EWL: A More Political Stable, But Too Expensive Alternative To The U.S.
iShares MSCI Switzerland ETF's high allocation to Nestle, Roche, and Novartis poses diversification risks. Read why EWL is a Hold despite Switzerland's stability.
Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Oak Hill Bio has entered into an exclusive license agreement with Roche to obtain global rights for rugonersen for Angelman syndrome.
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large ...
European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy | RHHBY Stock News
European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
Basel, 14 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for th...
Roche: Forget Tariffs And Focus On The Positives -- There Are Many
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros Corporation (NASDAQ: OMER) on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML) . AML is...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.